Medical News

RSS

Columbia University, Sanofi-aventis collaborate to develop innovative diabetes medicines

Sanofi-aventis announced today a research collaboration with Columbia University Medical Center for the development of innovative diabetes medicines.

25 Mar 2011

USPTO issues Notice of Allowance to AlphaRx ARX8203 pain product candidate

AlphaRx Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its lead pain product candidate code named ARX8203, a potentially safer drug intended for pain treatment.

25 Mar 2011

Study: Surgeon enthusiasm linked to high spinal procedure rates

Surgeons in some areas are more likely to recommend surgery for low back problems—and those differences in "surgeon enthusiasm" are a major factor driving regional variations in spinal surgery rates, suggests a study in the March 14 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

25 Mar 2011

Loyola earns recognition for pathology research

Loyola University Medical Center tied for fourth place in a recent research competition for pathologists-in-training that included 100 academic medical centers worldwide.

25 Mar 2011

Quantum dots allow stem cell therapy monitoring for brain injury

A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

25 Mar 2011

AACP selects Maryland professor for Pharmacy Educator Award

The American Association of Colleges of Pharmacy has selected innovative educator and mentor Robert Beardsley, RPh, PhD, MS, to receive the group's prestigious 2011 Robert K. Chalmers Distinguished Pharmacy Educator Award.

25 Mar 2011

Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today positive top-line results of a Phase 1 study of PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin and immediate-release omeprazole.

25 Mar 2011

Opinions: Using taxes to reduce poverty; fighting TB; meeting global food demands

To improve living standards and create jobs," African governments "need to provide their citizens with better health care, better education, more infrastructure. How to pay for this - in a way that is both fair and efficient - is a question that all governments face," Mark Plant, deputy director of the IMF's African Department, writes in a BusinessDay opinion piece where he describes how increased tax revenues in several African countries have led to "in-roads into poverty reduction."

25 Mar 2011

Agilent opens new lab facility in Bangalore, India

Agilent Technologies Inc. has expanded its Life Sciences and Chemical Analysis Center of Excellence in Bangalore.

25 Mar 2011

Researchers identify gene that can predict hypersensitivity to epilepsy drug

Research published this week in the New England Journal of Medicine. A multinational team of scientists led by the Royal College of Surgeons in Ireland and the University of Liverpool has identified a gene that could indicate if epilepsy patients starting a common drug treatment are likely to experience side-effects ranging from a mild skin irritation to the potentially fatal Steven-Johnson Syndrome.

25 Mar 2011

Molecular Devices signs distribution agreement with ChanTest

Molecular Devices, Inc. and ChanTest Corporation, leading providers of ion channel and GPCR drug discovery tools and solutions, have signed an agreement for Molecular Devices to distribute ChanTest's extensive portfolio of ion channel and GPCR cell lines on a non-exclusive basis.

25 Mar 2011

APC-300 drug significantly inhibits pancreatic cancer cell growth: Adamis

Adamis Pharmaceuticals Corporation announced today that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells.

25 Mar 2011

New study implicates microRNAs in panic disorder

A new study published in the current issue of Biological Psychiatry now implicates one type of molecular switch, microRNAs, in panic disorder.

25 Mar 2011

Children with epilepsy more likely to have psychiatric symptoms

A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.

25 Mar 2011

Researchers create hand and finger gesture controlled microscope

The multitouch microscope integrates two Finnish innovations and brings new dimensions into teaching and research.

25 Mar 2011

FDA approves Medtronic's Consulta and Syncra pacemaker systems

Medtronic, Inc. today announced that the U.S. Food & Drug Administration has approved its Consulta and Syncra cardiac resynchronization therapy-pacemaker systems.

25 Mar 2011

Study finds significant increase in MRSA infections during summer, autumn months

A new study from Rhode Island Hospital has found a significant increase in the occurrence of methicillin-resistant Staphylococcus aureus infections in the summer and autumn months.

25 Mar 2011

Young adults with religious involvement more likely to become obese in middle-age

Could it be the potato salad? Young adults who frequently attend religious activities are 50 percent more likely to become obese by middle age as young adults with no religious involvement, according to new Northwestern Medicine research.

25 Mar 2011

VARI, Gentel Biosciences receive U.S. Patent for new glycan detection technology

Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute, a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.

25 Mar 2011

Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers

Oncolytics Biotech Inc. today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.

25 Mar 2011